Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2009Journal of Cutaneous Medicine and Surgery

Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis

View Full Paper
Ask AI
Bookmark
Share

Authors

RBRobert BissonnetteGoethe University FrankfurtVHVincent HoUniversity of LondonRLRichard G. LangleyDalhousie University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bissonnette et al. (2009) studied this question.

synapsesocial.com/papers/6a8cf8bda0da40c23df5579ehttps://doi.org/10.2310/7750.2009.00023
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis1993 · 65 citations
  2. 2Lack of Significant Skeletal Changes after Long-Term, Low-Dose Retinoid Therapy: Case Report and Review of the Literature2006 · 33 citations
  3. 3Subfulminant hepatitis B after infliximab in Crohn’s disease: Need for HBV-screening2006 · 158 citations
  4. 4Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies2006 · 2,485 citations
  5. 5Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients1998 · 823 citations